';
Intellectual & Developmental Disabilities

As you are aware, The Pennsylvania Office of Developmental Programs (ODP) has proposed adopting a system under which private provider agencies would be graded on their performance on a number of ODP-selected indicators of quality. Underlying this model is the assumption that service providers should be able to offer all necessary supports and services to a broad range of individuals throughout their lives. In a sense, providers will be shaped towards becoming more comprehensive in their offerings.

RCPA is interested in assessing the extent to which the intellectual disability providers are prepared to meet these new expectations. By assessing readiness, we hope to be able to offer suggestions to ODP that will ease the transition to this new service model.

I am inviting you to assist us in our advocacy efforts by completing a survey that will help assess our readiness. A PDF copy of the survey can be accessed here, so that you can preview the questions and gather any information you believe will be helpful in completing the survey. When you are ready to complete the survey, you can access the survey online using this link. Please complete the survey by COB on Tuesday February 20, 2024.

If you have any questions regarding this survey, please contact either Dr. Scott Spreat (via email or 215-750-4015) or Carol Ferenz (via email or 717-364-3282).

Thank you for your participation.

Richard S. Edley
President and CEO
RCPA

A Request for Proposals (Solicitation/Project#:6100060351) for a single contract in the eastern region of Pennsylvania with the Office of Vocational Rehabilitation (OVR) for the PA SWTCIE Grant’s InVEST Project has been issued. Interested parties should access information regarding this opportunity on the PA eMarketplace website.

The InVEST Project is seeking to increase competitive integrated employment outcomes for individuals who are engaged, or are considering engagement, in subminimum wage employment. The project is funded through the Disability Innovation Fund (DIF) Subminimum Wage to Competitive Integrated Employment Grant, a federal model demonstration grant from the Rehabilitation Services Administration (PR Award # H421D220003).

Photo by Glenn Carstens-Peters on Unsplash

The Office of Child Development and Early Learning (OCDEL) has announced the successful migration of data from the old registry site to the new Infant/Toddler Early Intervention Provider Registry website. All users can now log in to the new site and access all of their information. Users will still be able to log into the old site for any Early Childhood Education related activities but will now use the new site for all Early Intervention related tasks.

Please update your bookmarks with the new link. If you encounter any issues or have questions, please utilize the “Contact Us” button on the site or email directly. For all other Early Intervention related questions, please contact RCPA Policy Director Jim Sharp.

The Office of Developmental Programs (ODP) has shared ODPANN 24-015.The purpose of this communication is to provide guidance for implementing changes to assistive technology and remote supports in the amendments to the Consolidated, Community Living, Person/Family Directed Support (P/FDS) and Adult Autism Waivers. View the announcement and the forms below for details.

The Office of Developmental Programs (ODP) has shared ODPANN 24-014. The purpose of this announcement is to communicate that Temple University Harrisburg Certified Investigator Program and ODP will be facilitating Forums for Certified Investigators (CI) and others involved in the incident investigation process. This also announces the posting of Q&A documents from past CI Forums on myODP. Please view the announcement for information and details.

This Request for Proposals (RFP) requires performance analysis activities to administer the requirements of the CMS 1915(b)(4) waiver for licensed residential habilitation, unlicensed residential habilitation, supported living, and life-sharing services, as well as for supports coordination services currently offered in all ODP 1915(c) waiver programs.

Tasks to support administering the requirements of the 1915(b)(4) waiver include but are not limited to: data collection, analysis and reporting, Provider Contract Management, managing a public facing website, and providing and maintaining an information support system.

All offerors are required to create a user profile within the DHS JAGGAER portal. Please visit here to access the portal.

Proposals are due Tuesday, March 5, 2024, by 12:00 pm. Visit PA eMarketplace for more information and to apply.

RCPA is delighted to share our 2023 Year in Review! We’re confident that this review will provide you with valuable insights, and inspire you as we highlight some of our significant achievements. This past year, we have embarked on groundbreaking initiatives and celebrated remarkable successes, all thanks to our collective efforts. As we step into 2024, we remain optimistic about reaching new heights together, and hope this review fuels your enthusiasm for what we can all accomplish in the coming year.

The Office of Developmental Programs (ODP) has shared this important announcement from the U.S. Food and Drug Administration (FDA) about a recall of two cough medicine products by Robitussin. The products are Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult. Please see the specific Lot Numbers below that are involved in the recall.  If you have one of these products with the matching Lot Number, stop use immediately and contact your health care provider.


Haleon Issues Voluntary Nationwide Recall of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult Products Due to Microbial Contamination

Summary
Company Announcement Date: January 24, 2024
FDA Publish Date: January 24, 2024
Product Type: Drugs
Reason for Announcement: Microbial Contamination
Company Name: Haleon
Brand Name: Robitussin
Product Description: Cough syrups

Haleon is voluntarily recalling eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult to the consumer level. The product is being recalled due to microbial contamination.

In immunocompromised individuals, the use of the affected product could potentially result in severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections are not likely to occur. However, the occurrence of an infection that may necessitate medical intervention cannot be completely ruled out. To date, Haleon has not received any reports of adverse events related to this recall.

Robitussin Honey CF Max Day and Nighttime are cough syrups indicated for the temporary relief of symptoms occurring with cold or flu, hay fever, or other respiratory allergies. This recall covers only the following lots:

Product Lot Number Expiry Date
ROBITUSSIN HONEY CF MAX
DAY ADULT 4OZ
T10810 31OCT2025
ROBITUSSIN HONEY CF MAX
DAY ADULT 8OZ
T08730
T08731
T08732
T08733
T10808
31MAY2025
31MAY2025
31MAY2025
31MAY2025
30SEP2025
ROBITUSSIN HONEY CF MAX
NT ADULT 8OZ
T08740 T08742 30JUN2026
30JUN2026

Haleon is notifying its distributors and customers directly and has provided them with instructions for the return of all recalled products. Consumers that have purchased the product listed should stop consumption immediately. Please call our Consumer Relations team at +1-800-245-1040 (Monday through Friday 8:00 am – 6:00 pm Eastern Time) or reach out via email.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

  • Complete and submit the report online
  • Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.